Compare BIVI & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIVI | TRIB |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 14.2M |
| IPO Year | 2013 | 1996 |
| Metric | BIVI | TRIB |
|---|---|---|
| Price | $2.18 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 177.7K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.51 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $0.31 |
| 52 Week High | $9.09 | $3.44 |
| Indicator | BIVI | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 35.90 |
| Support Level | $1.22 | $0.31 |
| Resistance Level | N/A | $0.75 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 80.36 | 24.21 |
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.